{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:28:57Z","timestamp":1777577337154,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Analysis of etanercept biosimilars in pediatric patients with juvenile idiopathic arthritis (JIA) in comparison with the etanercept originator in terms of efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with JIA who started treatment with either the etanercept originator or a biosimilar after January 1, 2017, were selected from the German BIKER registry (Biologics in Paediatric Rheumatology Registry). Furthermore, patients who started therapy with the originator and switched to a biosimilar during the course of therapy were identified. For both patient groups, disease activity and safety were examined and compared separately.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After January 1, 2017, 348 patients started treatment with the etanercept originator (n = 293) or a biosimilar (n = 55). Another 57 patients switched to a biosimilar during the course of therapy. A significant decrease or a stable remission of disease activity was observed in both patient groups. The safety profiles were comparable, and frequencies and types of adverse events (AEs) and serious AEs were similar in patients starting therapy with the originator or a biosimilar. Only injection site reactions occurred slightly more frequently under biosimilar therapy, without having an impact on therapy adherence. In patients who switched therapy, the AE rate per 100 patient\u2010years was comparable before (26.4) and after (32.1) the switch.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with JIA who require treatment with etanercept, the originator is still used much more frequently. However, our study highlights the equivalence of etanercept biosimilars for therapy for JIA. Increased use of these biosimilars in pediatric patients can therefore be recommended without hesitation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11325","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T15:22:59Z","timestamp":1630077779000},"page":"779-787","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study"],"prefix":"10.1002","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-8827","authenticated-orcid":false,"given":"Franz","family":"Thiele","sequence":"first","affiliation":[{"name":"Asklepios Clinic Sankt Augustin Sankt Augustin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8710","authenticated-orcid":false,"given":"Ariane","family":"Klein","sequence":"additional","affiliation":[{"name":"Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, and University of Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5656-9165","authenticated-orcid":false,"given":"Anton","family":"Hospach","sequence":"additional","affiliation":[{"name":"Klinikum Stuttgart Olgahospital Stuttgart Stuttgart Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-5103","authenticated-orcid":false,"given":"Daniel","family":"Windschall","sequence":"additional","affiliation":[{"name":"Northwest German Rheumatology Center St. Josef Stift Sendenhorst Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Mrusek","sequence":"additional","affiliation":[{"name":"Practice for Paediatric Rheumatology Baden\u2010Baden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Michael","family":"Ruehlmann","sequence":"additional","affiliation":[{"name":"Practice for Paediatric Rheumatology Goettingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-7832","authenticated-orcid":false,"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[{"name":"Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, and University of Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0327-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1170-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108447"},{"key":"e_1_2_9_5_1","unstructured":"European Medicines Agency.Guideline on similar biological medicinal products containing biotechnology\u2010derived proteins as active substance: non\u2010clinical and clinical issues.2014. URL:https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010similar\u2010biological\u2010medicinal\u2010products\u2010containing\u2010biotechnology\u2010derived\u2010proteins\u2010active_en\u20102.pdf."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262388"},{"key":"e_1_2_9_7_1","first-page":"5","article-title":"Biosimilars and the extrapolation of indications for inflammatory conditions","volume":"11","author":"Tesser JR","year":"2017","journal-title":"Biologics"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207588"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15152"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001079"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12540"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014886"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1462-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04774-3"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/msc.1239"},{"key":"e_1_2_9_19_1","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.ICH Harmonized Guideline. Integrated addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2). URL:http:\/\/www.ich.org."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar594"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000757"},{"key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/annrheumdis-2017-eular.3672","article-title":"AB0377 Switching from bio\u2010original etanercept to biosimilar etanercept sb4: patient acceptability and outcomes in the real world","volume":"76","author":"Holroyd C","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14605"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-313404"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2012-131730"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.5.622"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2012.03.039"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1103733"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0085-z"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/annrheumdis-2017-eular.2889","article-title":"FRI0200 Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy","volume":"76","author":"Tweehuysen L","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_32_1","first-page":"835","article-title":"Switching from reference product etanercept to the biosimilar sb4 in a real\u2010life setting: follow\u2010up of 147 patients","volume":"76","author":"Sigurdardottir V","year":"2017","journal-title":"Poster Presentations: Ann Rheum Ann"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210742"},{"key":"e_1_2_9_34_1","unstructured":"Gemeinsamer Bundesausschuss.Biologische Arzneimittel: G\u2010BA beschlie\u00dft Hinweise f\u00fcr eine wirtschaftliche Verordnungsweise von Biologika und Biosimilars.2020. URL:https:\/\/www.g\u2010ba.de\/presse\/pressemitteilungen\u2010meldungen\/886\/."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209166"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1090313"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11325","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11325","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:27:10Z","timestamp":1759418830000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/acr2.11325"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11325","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"assertion":[{"value":"2021-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}